AR and prostate cancer: On the other hand, pTVG-AR, encoding the ligand-binding domain of androgen receptors, targets the androgen receptor (AR), which plays a pivotal role in the development and progression of prostate cancer, particularly in castration-resistant prostate cancer (CRPC).